comparemela.com

Latest Breaking News On - Mind medicine mindmed inc - Page 6 : comparemela.com

MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

/PRNewswire/ Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies.

Matthias liechtiMiri halperin wernliPrnewswire mind medicine mindmed incUniversity hospital baselLysergic acid diethylamideHalperin wernliExecutive presidentUniversity hospitalMind medicine mindmed incHealth care amp hospitalsMedical pharmaceuticalsMental healthClinical trials amp medical discoveries

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

/PRNewswire/ Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing.

Robert barrowExchange commissionCompany articlesMedicine mindmed incMind medicineMultiple voting sharesEffective dateSubordinate voting sharesMultiple voting shareVoting sharesChief executive officerMind medicine mindmed inc

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

/PRNewswire/ Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing.

Robert barrowExchange commissionCompany articlesMedicine mindmed incMind medicineMultiple voting sharesEffective dateSubordinate voting sharesMultiple voting shareVoting sharesChief executive officerMind medicine mindmed inc

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

/PRNewswire/ Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing.

Robert barrowExchange commissionNational institute of mental healthCompany phaseDrug administrationMedicine mindmed incMind medicineInvestigational new drugChief executive officerGeneralized anxiety disorderNational instituteMental healthMajor depressive disorderLooking statementsMind medicine mindmed inc

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

/PRNewswire/ Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing.

Robert barrowExchange commissionNational institute of mental healthCompany phaseDrug administrationMedicine mindmed incMind medicineInvestigational new drugChief executive officerGeneralized anxiety disorderNational instituteMental healthMajor depressive disorderLooking statementsMind medicine mindmed inc

vimarsana © 2020. All Rights Reserved.